In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $49.97 in the last session, down -4.82% from day before closing price of $52.50. In other words, the price has decreased by -$4.82 from its previous closing price. On the day, 1.76 million shares were traded. RNA stock price reached its highest trading level at $54.1568 during the session, while it also had its lowest trading level at $49.81.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.76 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on September 24, 2024, initiated with a Buy rating and assigned the stock a target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.BofA Securities initiated its Buy rating on May 03, 2024, with a $40 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 06 ’24 when MacLean Michael F sold 106,319 shares for $45.56 per share. The transaction valued at 4,843,979 led to the insider holds 94,093 shares of the business.
MICHAEL MACLEAN bought 106,319 shares of RNA for $4,793,924 on Nov 06 ’24. On Oct 21 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 5,000 shares for $46.63 each. As a result, the insider received 233,168 and left with 14,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5961870848 and an Enterprise Value of 4380894720. For the stock, the TTM Price-to-Sale (P/S) ratio is 589.12 while its Price-to-Book (P/B) ratio in mrq is 3.95. Its current Enterprise Value per Revenue stands at 433.023 whereas that against EBITDA is -13.604.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $5.68. The 50-Day Moving Average of the stock is 10.48%, while the 200-Day Moving Average is calculated to be 45.96%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.31M shares per day over the past 3-months and 1266390 shares per day over the past 10 days. A total of 119.31M shares are outstanding, with a floating share count of 110.68M. Insiders hold about 7.24% of the company’s shares, while institutions hold 95.14% stake in the company. Shares short for RNA as of 1730332800 were 14659552 with a Short Ratio of 11.21, compared to 1727654400 on 14773809. Therefore, it implies a Short% of Shares Outstanding of 14659552 and a Short% of Float of 15.15.
